SAN DIEGO—Researchers at the University of California–San Diego (UCSD) and the University of California–San Francisco (UCSF) have mapped out how hundreds of mutations involved in two types of cancer affect the activity of discrete groups of proteins that are the ultimate actors behind the disease, reports published today revealed. The work points the way to identifying new precision treatments that may skirt side effects common with much current chemotherapy. The effort, dubbed Cancer Cell Mapping Initiative (CCMI), is led by Trey Ideker, professor at UCSD School of Medicine and Moores Cancer Center, and Nevan Krogan, director of the Quantitative Biosciences Institute at UCSF, who are co-senior authors on a set of three related studies that describe the map. The papers appear in Friday’s online issue of Science. “The bottom line is that we’re elevating the conversation about cancer from individual genes to whole protein complexes,” Ideker said. “For years, different groups …